Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Study Type
OBSERVATIONAL
Enrollment
185
Second-line treatment with paclitaxel/ramucirumab vs other regimens
Hellenic Oncology Cooperative Group
Athens, Greece
Progression-free survival
The primary endpoint of interest was the assessment of progression-free survival (PFS1), defined as the time interval from the initiation of second-line treatment to the date of discontinuation (due to any reason), first documented progression, death from any cause or last contact, whichever occurred first.
Time frame: From the initiation of second-line treatment to the date of discontinuation (due to any reason), first documented progression, death from any cause or last contact, through study completion, up to 2 years
Overall survival
overall survival (OS), defined as the time interval from the date of disease progression to the date of death from any cause or last contact.
Time frame: From the date of disease progression to the date of death from any cause or last contact, through study completion, up to 2 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.